TFII.TO -1.7C 0.13MU -51.63CRWD 5.64PANW 6.15SNOW -4.82V -0.14MAL.TO -0.14
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

25.21
+0.20 (0.78%)
as of Aug 3, 2026, 1:30:21 pm Market Open.
581 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconAug 2, 2026, 12:00 am

This summary was created by AI, based on 23 opinions in the last 12 months.

Pfizer Inc. (PFE) is currently facing challenges following its pandemic-driven peak during which it surged due to COVID-19 vaccine sales. Experts have pointed out a lack of earnings momentum and concerns over a patent cliff, as key drugs have come off patent and the company needs to innovate to develop new blockbuster drugs. Despite these challenges, many analysts emphasize the attractive dividend yield, which remains around 6-8%. The company is pivoting towards growth areas such as obesity and oncology, and while there's a general belief that PFE is under pressure, patience from investors could yield positive results. Several insights indicate that while it may not attract immediate growth, the company’s efforts in acquisitions and drug development could eventually pay off, given time.

consensus icon
Consensus
Hold
valuation icon
Valuation
Undervalued
review icon
Similar
MRK
BUY

Pfizer Inc(PFE)

Mar 21, 2006
The fundamental outlook is improving. The worst is behind it. The company is swimming in cash. There could be another dividend increase.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$26.31

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Mar 15, 2006
Pfizer is a large cap pharma. Probably the largest pharma company in the world. Has suffered along with the rest of the industry. It is well positioned. Very attractive. Good dividend yield. Predicts it will continue to grow 12-15%.
Photo of Laura WallaceLaura Wallace
Owned
Unlock Rating
$25.95

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
WATCH

Pfizer Inc(PFE)

Feb 28, 2006
Developed a new inhalant insulin product. Good product as diabetes continue to grow. They have had some litigation problems and some patents will be expiring. Worth watching it.
Photo of David BaskinDavid Baskin
No
Unlock Rating
$26.19

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
TRADE

Pfizer Inc(PFE)

Feb 24, 2006
They need to do some building of pipeline, so the stock will be going sideways for awhile, but there will be demand.
Photo of David DriscollDavid DriscollUnlock Rating
$26.14

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Feb 22, 2006
He likes this industry. The growth is not what it used to be. Evaluations are cheaper than they have been in a long time. Growth stocks are cheaper than they have been in last 20 years.
Photo of John ZechnerJohn Zechner
Owned
Unlock Rating
$26.19

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Feb 14, 2006
It's in their top 10 of their US-value 50. It's currently below what he paid for it.
Photo of Brian Acker, CABrian Acker, CAUnlock Rating
$25.50

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Feb 13, 2006
(A Top Pick Dec 5/05. Up 20%.) They got a positive legal ruling on Lipator which protects their patent. They increased their dividend. Have just announced that they will be doing something with their consumer product division, spinning out to shareholders or selling it.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$25.58

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Feb 02, 2006
This is a value stock and is showing up under his parameters as a buy. As a strategic investor, this would be the time to buy this.
Photo of Jim O'ShaughnessyJim O'Shaughnessy
Owned
Unlock Rating
$25.78

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
SELL

Pfizer Inc(PFE)

Jan 31, 2006
Thinks the heyday of those large pharmaceutical companies have come and gone. The pipeline is relatively bare. They have reached a point in time when they are trying to cut costs at a greater rate than the revenue decline. Not a good business to be in at this point.
Photo of Ian NakamotoIan Nakamoto
Owned
Unlock Rating
$25.68

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Jan 20, 2006
4% dividend yield. Trades had about 11 X earnings. They should continue to do well.
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$24.71

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Dec 28, 2005
Uses a two-pronged approach. Teva (TEVA-Q) is his growth drug stock and Pfizer (PFE-N) is his value drug stock. Thinks the tide has turned for this stock. Just won the Lipitor patent case giving them patent protection through to 2011. Have upped their dividend.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$23.60

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Dec 22, 2005
Big pharmaceuticals have just been decimated this year. This one just won a major patent challenge in the last few days, so the sentiment has turned a bit. It will take some time for these stocks to give the kind of return that we were used to. Still phenomenally profitable. Very cheap, trading at 11 X earnings. Good dividend.
Photo of Laura WallaceLaura Wallace
Owned
Unlock Rating
$24.06

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Dec 13, 2005
He has a 2-pronged approach to the pharmaceutical area. Has a growth segment through Teva (TEVA-Q) and this one is his value play. Dividend is now about 4.5%. It’s selling at about 12/13 X next year’s earnings. Have a great pipeline coming along.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$22.31

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Dec 12, 2005
The world seems to hate the large US phamaceuticals right now, but the valuation now is better than he has ever seen it. They generate good cash and can buy a bit of a pipeline if they have to.
Photo of John ZechnerJohn Zechner
Owned
Unlock Rating
$20.94

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Dec 06, 2005
The largest pharmaceutical company in the world. Have a good pipeline of drugs. Well-managed.
Photo of Don ReedDon Reed
Owned
Unlock Rating
$21.14

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
Showing 631 to 645 of 885 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

EOG 3.18$148.69
SLB 0.68$49.59
SHEL 1.47$91.98
AAPL -24.52$308.91
AMZN 36.08$271.58
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video

Today's Top Picks

TFII.TO -1.7$13.38
C 0.13$132.45
MU -51.63$823.03
CRWD 5.64$190.86
PANW 6.15$331.83

Popular Articles

Latest Sell Signals

AAPL -24.52$308.91
AAPL -24.52$308.91
AAPL -24.52$308.91
T.TO -1.7$13.38
CCA.TO -1.1$59.1

Most Recent Experts

Amy Raskin, CIO, Chevy Chase Trust

Amy Raskin, CIO, Chevy Chase Trust

Chevy Chase Trust

Stephanie Link, Chief investment strategist, Hightower

Stephanie Link, Chief investment strategist, Hightower

Hightower

Rob Sechan, Managing Partner, New Edge Capital

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Jim Lebenthal

Jim Lebenthal

Cerity Partners

Brianne Gardner

Brianne Gardner

Raymond James

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica

You may also like